[Regulations concerning data transparency- a comparison between the USA and Europe]

Area of Science:

• Pharmaceutical research
• Regulatory affairs
• Public health

Background:

• The US Food and Drug Administration Amendment Act (FDAAA) section 801 mandates registration and publication of clinical trial data, including results, on ClinicalTrials.gov since 2007.
• In the European Union, clinical trials are registered in the EudraCT database, but the data remains confidential and inaccessible to the public.
• The German Drugs Act (§ 42b) requires reporting of clinical trial results on PharmNet.Bund since 2011 to enhance information for healthcare professionals and patients.

Purpose of the Study:

• To compare and contrast clinical trial registration and results publication regulations in the US and EU.
• To highlight the importance of transparency in clinical trial reporting for public health.
• To evaluate the effectiveness of existing regulations in preventing publication bias.

Main Methods:

• Comparative analysis of regulatory frameworks in the US and EU regarding clinical trial transparency.
• Review of relevant legislation, including FDAAA section 801 and German Drugs Act § 42b.
• Examination of publicly accessible clinical trial databases (ClinicalTrials.gov, EudraPharm).

Main Results:

• The US mandates comprehensive public disclosure of clinical trial registration and results.
• EU regulations currently maintain strict confidentiality of clinical trial data, with limited public access.
• Germany has implemented a system for reporting trial results to improve information dissemination.

Conclusions:

• The US model serves as a benchmark for comprehensive public information on clinical trials.
• Enhanced transparency in clinical trial reporting is crucial for informed decision-making by doctors and patients.
• Adoption of similar transparency measures globally can help mitigate publication bias and advance medical research.